- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment: Study

Adults receiving semaglutide for obesity treatment experienced greater improvements in several measures of disordered eating, eating disorder symptoms, and body image concerns compared with participants receiving placebo, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. The study was published today in the International Journal of Eating Disorders.
"Given the growing use of GLP-1 medications for obesity treatment, there has been interest in understanding how these therapies affect eating disordered behaviors and body image," said Kelly Costello Allison, PhD, director of Penn’s Center for Weight and Eating Disorders (CWED) and the study's first author who presented findings of the study at ObesityWeek 2026 in Washington, D.C. "Our findings suggest that semaglutide not only supports weight loss but may also improve several measures of eating disorder psychopathology and loss of control eating in many patients," said Jena Tronieri, PhD, senior research investigator at Penn’s CWED and senior author of the study.
Improvements in eating behaviors and body image
The study included 120 adults seeking treatment for obesity. Participants were randomly assigned to receive either semaglutide 2.4 mg or placebo alongside a structured lifestyle intervention that included dietary counseling and physical activity guidance. Participants receiving semaglutide experienced substantially greater weight loss than those receiving placebo, losing an average of approximately 15% of their body weight after 60 weeks, compared with about 3% in the placebo group.
Over the course of the 60-week study, participants treated with semaglutide experienced significantly greater improvements in several measures of eating-related and psychological health compared with those receiving placebo. The medication was associated with larger reductions in loss-of-control eating, overall eating disorder psychopathology, and concerns related to body weight and shape. Participants in the semaglutide group also reported greater improvements in feelings of body dissatisfaction and body image.
Among individuals who entered the study with binge eating episodes or full or subthreshold binge-eating disorder, those receiving semaglutide were more likely to achieve remission and abstinence from binge eating behaviors. The emergence of new eating disorder symptoms and clinically meaningful worsening of eating-related psychopathology were uncommon in both treatment groups, suggesting that semaglutide treatment was generally associated with improvements, rather than deterioration, in eating-related outcomes.
The researchers noted that while average outcomes were favorable, a small number of participants experienced disordered eating behaviors during the study, underscoring the importance of continued monitoring, particularly among individuals with a history of eating disorders. The authors noted that larger studies will be needed to further evaluate the relationship between GLP-1 medications and eating disorders, particularly among individuals with diagnosed binge-eating disorder or a history of other eating disorders.
"These results are encouraging, particularly for patients who struggle with both obesity and binge eating," said Allison. "At the same time, our findings highlight the importance of routinely assessing eating behaviors throughout treatment, particularly in patients with an eating disorder history, so that patients who develop concerning symptoms can receive appropriate care."
Reference:
Allison, K. C., T. A. Wadden, K. DeRouen, et al. 2026. “ Disordered Eating Attitudes and Behaviors in Individuals With BMI > 27 kg/m2 Treated by Semaglutide: A 60-Week Randomized Placebo-Controlled Trial.” International Journal of Eating Disorders 1–15. https://doi.org/10.1002/eat.70253.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

